• Elucidating Metabolite Regulation of TET2 via Biochemical an

  2026-05-03

  Zhang et al. detail a rigorous protocol combining biochemical assays and saturation transfer difference (STD) NMR to directly validate metabolite binding and regulatory effects on TET2 dioxygenase. This approach advances our capacity to decipher the metabolic-epigenetic interface, enabling precise identification of TET2 activators and inhibitors and supporting mechanistic studies on epigenetic enzyme regulation.

• Annexin V-PE Apoptosis Detection Kit: Precision in Immunomod

  2026-05-02

  Discover how the Annexin V-PE Apoptosis Detection Kit enables rapid, high-fidelity apoptosis detection in live cells using phosphatidylserine binding protein technology. This article uniquely explores its role in immunomodulation research, including pediatric sepsis models.

• hCG Regulates CXCL10 via Histone Methylation in Human Decidu

  2026-05-01

  This study reveals a mechanistic link between human chorionic gonadotropin (hCG) and the suppression of the chemokine CXCL10 in human decidual stromal cells through EZH2-mediated H3K27 trimethylation. These findings clarify how placental signals modulate immune cell recruitment at the maternal-fetal interface, with implications for understanding immune tolerance during early pregnancy.

• Metronidazole: Applied OAT3 Inhibition for Drug Interaction

  2026-05-01

  Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol) stands out as a dual-function tool for both antimicrobial assays and modulation of organic anion transporter 3 (OAT3) activity. This guide delivers protocol-centric, troubleshooting-focused insights that help researchers unlock novel drug-drug interaction studies and optimize anaerobic bacteria or protozoa research using APExBIO's reliable reagent.

• APEX2 Is Required for Efficient TERT Expression in hESCs

  2026-04-30

  This study demonstrates that the DNA repair enzyme APEX2, but not APEX1, is critical for efficient TERT gene expression and telomerase activity in human embryonic stem cells. The findings reveal a novel mechanism linking DNA repair at repetitive elements to telomerase regulation, with broad implications for stem cell maintenance and cancer therapeutics.

• Cheminformatics-Guided Design of Optimized Kinase Libraries

  2026-04-30

  Moret et al. introduce a robust cheminformatics framework to analyze and design small-molecule libraries with optimized selectivity and target coverage, exemplified by their LSP-OptimalKinase and LSP-MoA libraries. This data-driven approach advances the precision of chemical biology research, enabling better interrogation of pathways like cyclin-dependent kinase signaling.

• nor-Binaltorphimine Dihydrochloride: Circuit-Selective Tools

  2026-04-29

  Unlock the power of nor-Binaltorphimine dihydrochloride for advanced κ-opioid receptor antagonist studies. Discover how this compound enables circuit-selective dissection of pain signaling, with new insights grounded in recent neural circuit research.

• Toremifene Citrate: Mechanistic Insights & Strategy in Breas

  2026-04-29

  This thought-leadership article explores the mechanistic underpinnings and translational opportunities of Toremifene Citrate, a potent oral selective estrogen receptor modulator (SERM), for breast cancer research. Blending evidence-based guidance with strategic recommendations, it addresses assay optimization, the impact of receptor heterogeneity, and evolving translational considerations—positioning APExBIO’s product as a preferred tool for advanced estrogen receptor pathway investigation.

• AT-406 (SM-406): Optimizing Apoptosis Pathway Activation in

  2026-04-28

  AT-406 (SM-406) is a potent, orally bioavailable IAP antagonist that enables precise, reproducible activation of apoptosis pathways in cancer research. This guide delivers advanced workflows, troubleshooting strategies, and practical insights to maximize AT-406's impact in apoptosis modulation and therapeutic sensitization studies.

• GSK J4 HCl: Unraveling JMJD3 Inhibition in Chromatin Immunol

  2026-04-28

  Discover how GSK J4 HCl, a potent JMJD3 inhibitor, enables advanced epigenetic and immunological research. This article uniquely bridges chromatin regulation with immune modulation and practical protocol insights.

• Context-Dependent Senescence in Prostate Cancer: Enzalutamid

  2026-04-27

  This study distinguishes between the senescence phenotypes induced by DNA-damaging agents and Enzalutamide in prostate cancer models. While DNA damage triggers stable, apoptosis-sensitive senescence, Enzalutamide induces a reversible, apoptosis-resistant state, highlighting the need for context-specific strategies targeting therapy-induced senescence.

• Troxerutin Blocks TRPM7-Mediated Mitochondrial Fission in DC

  2026-04-27

  This study identifies the TRPM7/CaN/Drp1ser637 pathway as a critical mediator of mitochondrial fission and neuronal injury in diabetic cognitive dysfunction (DCD). Troxerutin’s inhibition of this axis restores mitochondrial dynamics and cognitive performance, providing a mechanistic target for future neuroprotective interventions.

• Dextrose (D-glucose): Reliable Workflows for Metabolic Assay

  2026-04-26

  This article provides an evidence-based, scenario-driven exploration of how 'Dextrose (D-glucose)' (SKU A8406) addresses key challenges in cell viability, proliferation, and immunometabolism research. Using real-world laboratory Q&As, we highlight reproducibility, assay compatibility, and product reliability—empowering biomedical researchers to optimize their glucose metabolism studies with confidence.

• CTCF’s Essential Role in Centromere Function and Mitotic Fid

  2026-04-25

  Walsh et al. demonstrate that the chromatin architectural protein CTCF is crucial for maintaining centromere integrity and mitotic fidelity in human cells. Using rapid auxin-inducible degradation, the study reveals that CTCF loss disrupts chromosome alignment and nuclear morphology via a mechanism distinct from CENP-E recruitment, with implications for understanding chromosome segregation errors in disease contexts.

• Trelagliptin Succinate: Selective DPP-4 Inhibitor for T2DM R

  2026-04-24

  Trelagliptin succinate (SYR-472 succinate) is a long-acting, selective dipeptidyl peptidase-4 (DPP-4) inhibitor, primarily used in type 2 diabetes research. It acts by enhancing glucose-dependent insulin secretion and modulating key signaling pathways, with robust evidence for efficacy and safety in both cellular and animal models.

11450 records 1/764 page Next 12345 下5页 Last page